PATIENT REMINDER CARD

Important Safety Information

Patient reminder card regarding osteonecrosis of the jaw (ONJ)

This reminder card contains important safety information that you need to be aware of before and during treatment with denosumab (Prolia)

Your doctor has recommended that you receive denosumab (Prolia), which is used to treat osteoporosis and bone loss. These diseases involve thinning and weakening of the bones so they may break more easily.

A side effect called osteonecrosis of the jaw (ONJ) (bone damage in the jaw) has been reported rarely (may affect up to 1 in 1000 people) in patients receiving Prolia for osteoporosis. ONJ can also occur after stopping treatment.

It is important to try to prevent ONJ developing as it may be a painful condition that can be difficult to treat. In order to reduce the risk of developing ONJ, there are some precautions you should take:

Before starting treatment:

Tell your doctor/nurse (health care professional) if you have any problems with your mouth or teeth. Your doctor may ask you to undergo a dental examination if you:

- were previously treated with another medication being a bisphosphonate
- are taking medicines called corticosteroids (such as prednisolone or dexamethasone)
- are a smoker
- have cancer
- have not had a dental check up for a long time
- have problems with your mouth or teeth

While being treated:

- You should maintain good oral hygiene and receive routine dental check-ups. If you wear dentures you should make sure these fit properly.
- If you are under dental treatment or will undergo dental surgery (e.g. tooth extractions), inform your doctor and tell your dentist that you are being treated with Prolia.
- Contact your doctor and dentist immediately if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling, or non-healing of sores or discharge, as these could be signs of osteonecrosis of the jaw

Please read the package leaflet that comes with your medicine for further information.

Any suspected adverse reactions should be reported immediately to Amgen local representative or to the National Pharmacovigilance and Drug Safety Centre.

Amgen Local Representative in Saudi Arabia is Cigalah Group, Mobile: +966539455825 or email: drug-safety@cigalah.com.sa

The National Pharmacovigilance & Drug Safety Centre (NPC)
Saudi Food and Drug Authority (SFDA)
Fax: +966112057662
Email: npc.drug@sfda.gov.sa
Online: http://ade.sfda.gov.sa/